Vorobyev P O, Babaeva F E, Panova A V, Shakiba J, Kravchenko S K, Soboleva A V, Lipatova A V
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, 125167 Russia.
Mol Biol (Mosk). 2022 Sep-Oct;56(5):751-763. doi: 10.31857/S0026898422050147.
Cancer is a leading causes of death. Despite significant success in the treatment of lymphatic system tumors, the problems of relapse, drug resistance and effectiveness of therapy remain relevant. Oncolytic viruses are able to replicate in tumor cells and destroy them without affecting normal, healthy tissues. By activating antitumor immunity, viruses are effective against malignant neoplasms of various nature. In lymphoproliferative diseases with a drug-resistant phenotype, many cases of remissions have been described after viral therapy. The current level of understanding of viral biology and the discovery of host cell interaction mechanisms made it possible to create unique strains with high oncoselectivity widely used in clinical practice in recent years.
癌症是主要的死亡原因之一。尽管在淋巴系统肿瘤的治疗方面取得了显著成功,但复发、耐药性和治疗效果等问题仍然存在。溶瘤病毒能够在肿瘤细胞中复制并将其摧毁,而不影响正常的健康组织。通过激活抗肿瘤免疫,病毒对各种性质的恶性肿瘤都有效。在具有耐药表型的淋巴增殖性疾病中,病毒治疗后已有许多缓解病例的报道。目前对病毒生物学的理解水平以及宿主细胞相互作用机制的发现,使得近年来能够创造出具有高肿瘤选择性的独特毒株,并广泛应用于临床实践。